Verrica Pharmaceuticals Inc (NASDAQ:VRCA) insider Ted White purchased 2,505 shares of the stock in a transaction on Wednesday, August 15th. The shares were bought at an average cost of $15.69 per share, for a total transaction of $39,303.45. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of VRCA stock traded up $0.75 during trading on Friday, reaching $16.85. 23,550 shares of the company’s stock were exchanged, compared to its average volume of 46,291. Verrica Pharmaceuticals Inc has a twelve month low of $13.23 and a twelve month high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its earnings results on Tuesday, August 7th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.76). equities analysts forecast that Verrica Pharmaceuticals Inc will post -1.15 EPS for the current year.

Several research analysts have weighed in on the company. Jefferies Financial Group assumed coverage on Verrica Pharmaceuticals in a research report on Tuesday, July 10th. They set a “buy” rating and a $24.00 price target on the stock. Bank of America assumed coverage on Verrica Pharmaceuticals in a report on Tuesday, July 10th. They set a “buy” rating and a $26.00 target price on the stock. Finally, Cowen assumed coverage on Verrica Pharmaceuticals in a report on Tuesday, July 10th. They set an “outperform” rating and a $35.00 target price on the stock.

Hedge funds have recently bought and sold shares of the stock. Capital Investment Advisory Services LLC acquired a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth approximately $211,000. Laurion Capital Management LP acquired a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth approximately $395,000. Dean Capital Investments Management LLC acquired a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth approximately $676,000. Asymmetry Capital Management L.P. acquired a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth approximately $1,184,000. Finally, Kornitzer Capital Management Inc. KS acquired a new position in shares of Verrica Pharmaceuticals during the 2nd quarter worth approximately $2,905,000. 1.89% of the stock is currently owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals, Inc operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris.

Featured Story: Penny Stocks

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.